Snapshot
Abbott Laboratories reported $11.37B of revenue in Q3 2025, up 6.9% year over year, with diluted EPS of $0.94 and an operating margin of 18.1%.
- Revenue
- $11.37B
- YoY growth
- +6.9%
- Diluted EPS
- $0.94
- Operating margin
- 18.1%
$11.37B
Revenue
+6.9%
YoY growth
$0.94
Diluted EPS
18.1%
Operating margin
01 Key takeaways
What management said
- •These non-GAAP financial measures are reconciled with the comparable GAAP financial measures in our earnings news release and regulatory filings from today, which are available on our website at abbott.com.
- •Unless otherwise noted, our commentary on sales growth refers to organic sales growth, which is defined in the press release issued earlier today.
- •Today, we reported organic sales growth of 7.5% excluding COVID test sales.
- •Recently launched new products generated nearly half a billion dollars in sales this quarter and added more than 100 basis points to organic sales growth.
- •Strong brand recognition, combined with favorable demographic and dietary trends, including an increased focus on protein intake and immune system health, continues to fuel our growth.
- •Growth in adult nutrition was driven by 10% growth in international markets, where we continue to see strong demand for both Ensure and Glucerna.
- •To support future growth, we continue to invest in these well-known brands to ensure they evolve along with changing consumer preferences.
- •Moving to diagnostics, we saw modest sales growth in the quarter excluding COVID testing sales.
- •Excluding China, core lab diagnostics grew 7%, with markets such as the U.S.
- •showing an acceleration in growth in the third quarter compared to the growth in the first half of this year.
- •Our strong, consistent performance outside of China reflects durable underlying demand in markets around the world.
- •Turning to EPD, sales increased 7%, led by double-digit growth in our key 15 markets, highlighting broad-based demand and strong commercial execution.
SourcesCompany financials · earnings call
Last updated